Argentina

The primary regulatory authority in Argentina is the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), operating under the Ministry of Health (Ministerio de Salud de la Nación). ANMAT was established by Decree 1490/1992 and is responsible for the authorization, registration, surveillance, and quality control of medicines, medical devices, diagnostics, digital health technologies, and food products. The general approval process requires submission of a formal dossier to the relevant ANMAT department: the Centro para el Control de la Calidad (CCC) for pharmaceuticals and the Instituto Nacional de Tecnología Médica (INAME) for medical devices and diagnostics. Products must obtain a product registration certificate (Certificado de Autorización de Comercialización) before being marketed or procured in Argentina. Risk-based classification frameworks are applied, with higher-risk products subject to more rigorous technical and clinical review.

Key submission requirements include the mandatory appointment of a local regulatory representative (Apoderado Regulatorio), who must be domiciled in Argentina and is legally responsible for all regulatory interactions with ANMAT. Argentina generally accepts dossiers structured according to the Common Technical Document (CTD) format, particularly for pharmaceuticals, and aligns with Mercosur regional harmonization guidelines (Resoluciones GMC) where applicable. For medical devices, ANMAT follows a risk classification system broadly aligned with GHTF/IMDRF principles. Notable recent reforms include the implementation of Resolution 3622/2014 and subsequent updates streamlining device registration pathways, growing recognition of prior approvals from reference agencies such as the FDA, EMA, and Health Canada to facilitate expedited review tracks, and ongoing efforts to digitize the dossier submission process through the ANMAT online portal (GestioNet) to reduce administrative burden and improve review timelines.

Public procurement of health products in Argentina operates through a multi-layered federal and provincial structure. At the national level, the Ministerio de Salud de la Nación coordinates centralized procurement for federally funded programs, including essential medicines, vaccines, and medical supplies, largely through the Programa Remediar and the Dirección Nacional de Programas y Proyectos Sanitarios. The Oficina Nacional de Contrataciones (ONC), under the Secretaría de Gestión y Empleo Público, governs the legal framework for public tenders, with major acquisitions conducted via open competitive bidding (licitación pública) in accordance with Decree 1023/2001 and its regulations. Argentina's 23 provinces and the Autonomous City of Buenos Aires (CABA) operate their own health ministries and procurement agencies, creating significant decentralization: provincial hospital networks and provincial health insurance schemes (obras sociales provinciales) conduct independent tenders, and product registration requirements and pricing negotiations may vary across jurisdictions. The national social health insurance administrator, Superintendencia de Servicios de Salud (SSalud), also influences procurement through reimbursement listings that affect formulary access across the contributory obras sociales sector.

The private sector represents a substantial share of health product consumption in Argentina, channeled through a network of private distributors, pharmacy chains, and private hospitals, with pricing in the private channel subject to negotiation and, in some categories, voluntary or mandatory reference pricing mechanisms overseen by ANMAT and the Ministerio de Salud. International donor-funded procurement plays a more limited but present role: the Pan American Health Organization (PAHO) and UNICEF have historically supported vaccine and essential medicine supply for specific public programs, and the Global Fund has financed HIV, tuberculosis, and malaria commodity procurement in coordination with national authorities. Argentina does not currently maintain formal local manufacturing preference policies as mandatory procurement conditions, but government strategies under the Plan Nacional de Ciencia, Tecnología e Innovación Productiva have encouraged domestic pharmaceutical and biotech production capacity, and public procurement programs such as Remediar have periodically favored nationally produced generics to support the local industry and reduce import dependency.